Skip to main content

Table 5 Univariate proportional-hazards regression analysis of the influence of treatment delay on progression-free and overall survival in glioblastoma patients

From: Impact of delays in initiating postoperative chemoradiation while determining the MGMT promoter-methylation statuses of patients with primary glioblastoma

Group

Survival

Covariate

HR

95 % CI

Significance level

Study group

OS

Time delay to RT

0.95

0.90–0.99

0.04

Reference group

OS

Time delay to RT

0.99

0.98–1.00

0.13

Study group

PFS

Time delay to RT

0.97

0.93–1.01

0.18

Reference group

PFS

Time delay to RT

1.00

0.98–1.01

0.59

Study group

OS

Time delay to RT ≥24 days

0.43

0.23–0.83

0.01

Reference group

OS

Time delay to RT ≥24 days

0.59

0.40–0.89

0.01

Study group

PFS

Time delay to RT ≥24 days

0.49

0.26–0.92

0.03

Reference group

PFS

Time delay to RT ≥24 days

0.62

0.40–0.96

0.03

  1. OS: Overall survival; PFS: Progression-free survival; HR: Hazard ratio; CI: Confidence interval; RT: Radiation therapy